Effect of HMG-CoA reductase inhibitors on antimicrobial susceptibilities for Gram-Negative rods

被引:9
作者
Farmer, Aaron R. [1 ]
Murray, Clinton K. [1 ,2 ,3 ]
Mende, Katrin [1 ,2 ,4 ]
Akers, Kevin S. [1 ,2 ,3 ]
Zera, Wendy C. [1 ,2 ,4 ]
Beckius, Miriam L. [5 ]
Yun, Heather C. [1 ,2 ,3 ]
机构
[1] San Antonio Mil Med Ctr, Dept Med, Ft Sam Houston, TX USA
[2] San Antonio Mil Med Ctr, Infect Dis Serv, Ft Sam Houston, TX USA
[3] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
[4] Uniformed Serv Univ Hlth Sci, Infect Dis Clin Res Program, Bethesda, MD 20814 USA
[5] San Antonio Mil Med Ctr, Dept Clin Invest, Ft Sam Houston, TX USA
关键词
Antimicrobial susceptibilities; Gram negative rod; HMG-CoA reductase inhibitors; IN-VITRO; STATINS;
D O I
10.1002/jobm.201100614
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Epidemiologic evidence suggests a beneficial effect of HMG-CoA reductase inhibitors (statins) in sepsis, and in-vitro data exist for antimicrobial activity of statins against some bacteria and fungi. We examined whether statin exposure at physiologic concentrations enhances activity of selected antimicrobials against Acinetobacter baumannii, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Escherichia coli. Broth microdilution was performed with and without dose-ranging concentrations of lovastatin, fluvastatin, atorvastatin, pravastatin and simvastatin. No effects on antimicrobial activity were demonstrated.
引用
收藏
页码:336 / 339
页数:4
相关论文
共 18 条
  • [1] Studies on the Antibacterial Effects of Statins - In Vitro and In Vivo
    Bergman, Peter
    Linde, Charlotte
    Putsep, Katrin
    Pohanka, Anton
    Normark, Staffan
    Henriques-Normark, Birgitta
    Andersson, Jan
    Bjorkhem-Bergman, Linda
    [J]. PLOS ONE, 2011, 6 (08):
  • [2] Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America
    Boucher, Helen W.
    Talbot, George H.
    Bradley, John S.
    Edwards, John E., Jr.
    Gilbert, David
    Rice, Louis B.
    Scheld, Michael
    Spellberg, Brad
    Bartlett, John
    [J]. CLINICAL INFECTIOUS DISEASES, 2009, 48 (01) : 1 - 12
  • [3] Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole
    Chamilos, G
    Lewis, RE
    Kontoyiannis, DP
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (01) : 96 - 103
  • [4] In vitro activity of fluvastatin, a cholesterol-lowering agent, and synergy with fluconazole and itraconazole against Candida species and Cryptococcus neoformans
    Chin, NX
    Weitzman, I
    DellaLatta, P
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (04) : 850 - 852
  • [5] Çoban AY, 2010, MIKROBIYOL BUL, V44, P161
  • [6] The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases
    Friesen, JA
    Rodwell, VW
    [J]. GENOME BIOLOGY, 2004, 5 (11)
  • [7] Susceptibility of Acinetobacter strains isolated from deployed US military personnel
    Hawley, Joshua S.
    Murray, Clinton K.
    Griffith, Matthew E.
    McElmeel, M. Leticia
    Fulcher, Letitia C.
    Hospenthal, Duane R.
    Jorgensen, James H.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (01) : 376 - 378
  • [8] Janda S, 2010, J CRIT CARE, V25
  • [9] Unexpected antimicrobial effect of statins
    Jerwood, S.
    Cohen, J.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) : 362 - 364
  • [10] Changes in the Incidences of Multidrug-Resistant and Extensively Drug-Resistant Organisms Isolated in a Military Medical Center
    Keen, Edward F., III
    Murray, Clinton K.
    Robinson, Brian J.
    Hospenthal, Duane R.
    Co, Edgie-Mark A.
    Aldous, Wade K.
    [J]. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2010, 31 (07) : 728 - 732